Page 7 of 15
Journal of the American Chemical Society
19.
Castarlenas, R.; Di Giuseppe, A.; Pérez-Torrente, J. J.; Oro, L.
37.
Oballa, R. M.; Truchon, J.-F.; Bayly, C. I.; Chauret, N.; Day, S.;
A., The Emergence of Transition-Metal-Mediated Hydrothiolation of
Unsaturated Carbon–Carbon Bonds: A Mechanistic Outlook. Angew.
Chem. Int. Ed. 2012, 52 (1), 211-222.
Crane, S.; Berthelette, C., A generally applicable method for assessing
the electrophilicity and reactivity of diverse nitrile-containing
compounds. Bioorg. Med. Chem. Lett. 2007, 17 (4), 998-1002.
1
2
3
4
5
6
7
8
9
20.
Lowe, A. B., Thiol-yne ‘click’/coupling chemistry and recent
38.
Siklos, M.; BenAissa, M.; Thatcher, G. R. J., Cysteine proteases
applications in polymer and materials synthesis and modification.
Polymer 2014, 55 (22), 5517-5549.
21.
reaction mechanism and energetics of Markovnikov and anti-
Markovnikov addition in alkyne hydrothiolation reactions. Comput.
Theor. Chem. 2016, 1098, 13-21.
as therapeutic targets: does selectivity matter? A systematic review of
calpain and cathepsin inhibitors. Acta Pharm. Sin. B 2015, 5 (6), 506-
519.
Jayasree, E. G.; Reshma, S., A computational study on the
39.
Lushchak, V. I., Glutathione Homeostasis and Functions:
Potential Targets for Medical Interventions. J. Amino Acids 2012, 2012,
26.
40.
N.; Brayer, G. D.; Brömme, D., Identification of mouse cathepsin K
structural elements that regulate the potency of odanacatib. Biochem.
J. 2017, 474, 851-864.
22.
Sommer, S.; Weikart, N. D.; Linne, U.; Mootz, H. D., Covalent
Law, S.; Andrault, P.-M.; Aguda, A. H.; Nguyen, N. T.; Kruglyak,
inhibition of SUMO and ubiquitin-specific cysteine proteases by an in
situ thiol–alkyne addition. Bioorg. Med. Chem. 2013, 21 (9), 2511-2517.
23.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Arkona, C.; Rademann, J., Propargyl Amides as Irreversible
Inhibitors of Cysteine Proteases—A Lesson on the Biological Reactivity
of Alkynes. Angew. Chem. Int. Ed. 2013, 52 (32), 8210-8212.
41.
Copeland, R. A.; Basavapathruni, A.; Moyer, M.; Scott, M. P.,
Impact of enzyme concentration and residence time on apparent
activity recovery in jump dilution analysis. Anal. Biochem. 2011, 416
(2), 206-210.
42.
Irreversible Inhibition. SLAS Discovery 2017, 22 (1), 3-20.
43. Holdgate, G. A.; Meek, T. D.; Grimley, R. L., Mechanistic
enzymology in drug discovery: a fresh perspective. Nat. Rev. Drug
Discovery 2017, 17, 115.
44.
Radding, J. A.; McGee, J.; Weidner, J. Mechanism of Action Assays for
45.
In Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for
Medicinal Chemists and Pharmacologists, Second Edition, John Wiley &
Sons, Inc.: 2013.
24.
Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.;
Turk, D., Cysteine cathepsins: From structure, function and regulation
to new frontiers. Biochim. Biophys. Acta, Proteins Proteomics 2012,
1824 (1), 68-88.
Strelow, J. M., A Perspective on the Kinetics of Covalent and
25.
extracellular matrix remodeling: Extracellular matrix degradation and
beyond. Matrix Biol. 2018, DOI
26. Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.;
Vizovišek, M.; Fonović, M.; Turk, B., Cysteine cathepsins in
Strelow, J. M.; Dewe, W.; Iversen, P. W.; Brooks, H. B.;
Duong, L. T.; Falgueyret, J.-P.; Kimmel, D. B.; Lamontagne, S.; Léger, S.;
LeRiche, T.; Li, C. S.; Massé, F.; McKay, D. J.; Nicoll-Griffith, D. A.; Oballa,
R. M.; Palmer, J. T.; Percival, M. D.; Riendeau, D.; Robichaud, J.; Rodan, G.
A.; Rodan, S. B.; Seto, C.; Thérien, M.; Truong, V.-L.; Venuti, M. C.;
Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C., The discovery of
odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg.
Med. Chem. Lett. 2008, 18 (3), 923-928.
Copeland, R. A., Chapter 9. Irreversible Enzyme Inactivators.
46.
Cavallo, G.; Metrangolo, P.; Milani, R.; Pilati, T.; Priimagi, A.;
Resnati, G.; Terraneo, G., The Halogen Bond. Chem. Rev. 2016, 116 (4),
2478-2601.
47.
in maximum-likelihood refinement of macromolecular crystal
structures. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2014, 70 (Pt 12),
3124-3134.
27.
Stoch, S. A.; Zajic, S.; Stone, J.; Miller, D. L.; Van Dyck, K.;
Gutierrez, M. J.; De Decker, M.; Liu, L.; Liu, Q.; Scott, B. B.; Panebianco,
D.; Jin, B.; Duong, L. T.; Gottesdiener, K.; Wagner, J. A., Effect of the
Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in
Healthy Postmenopausal Women: Two Double-Blind, Randomized,
Placebo-Controlled Phase I Studies. Clin. Pharmacol. Ther. 2009, 86 (2),
175-182.
Pražnikar, J.; Turk, D., Free kick instead of cross-validation
48.
Drake, M. T.; Clarke, B. L.; Oursler, M. J.; Khosla, S., Cathepsin
K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and
Lessons Learned. Endocr. Rev. 2017, 38 (4), 325-350.
49.
S.; Szuhai, K.; Bromme, D.; Verheijen, J. H.; Hogendoorn, P. C. W.,
Cathepsin K Is the Principal Protease in Giant Cell Tumor of Bone. Am.
J. Pathol. 2004, 165 (2), 593-600.
28.
Brömme, D.; Lecaille, F., Cathepsin K inhibitors for
osteoporosis and potential off-target effects. Expert Opin. Invest. Drugs
2009, 18 (5), 585-600.
Lindeman, J. H. N.; Hanemaaijer, R.; Mulder, A.; Dijkstra, P. D.
29.
Brömme, D.; Panwar, P.; Turan, S., Cathepsin K osteoporosis
trials, pycnodysostosis and mouse deficiency models: Commonalities
and differences. Expert Opin. Drug Discovery 2016, 11 (5), 457-472.
50.
Edgington-Mitchell, L. E.; Rautela, J.; Duivenvoorden, H. M.;
30.
odanacatib. Nat. Rev. Drug Discovery 2016, 15 (10), 669-669.
31. Selent, J.; Kaleta, J.; Li, Z.; Lalmanach, G.; Brömme, D.,
Mullard, A., Merck
&
Co. drops osteoporosis drug
Jayatilleke, K. M.; van der Linden, W. A.; Verdoes, M.; Bogyo, M.; Parker,
B. S., Cysteine cathepsin activity suppresses osteoclastogenesis of
myeloid-derived suppressor cells in breast cancer. Oncotarget 2015, 6
(29), 27008-27022.
Selective Inhibition of the Collagenase Activity of Cathepsin K. J. Biol.
Chem. 2007, 282 (22), 16492-16501.
51.
Nicholson, G. C.; Malakellis, M.; Collier, F. M.; Cameron, P. U.;
32.
Dolman, S. J.; Gosselin, F.; O'Shea, P. D.; Davies, I. W., Selective
Holloway, W. R.; Gough, T. J.; Gregorio-King, C.; Kirkland, M. A.; Myers,
D. E., Induction of osteoclasts from CD14-positive human peripheral
blood mononuclear cells by receptor activator of nuclear factor κB
ligand (RANKL). Clin. Sci. 2000, 99 (2), 133.
metal-halogen exchange of 4,4′-dibromobiphenyl mediated by lithium
tributylmagnesiate. Tetrahedron 2006, 62 (21), 5092-5098.
33.
O’Shea, P. D.; Chen, C.-y.; Gauvreau, D.; Gosselin, F.; Hughes,
G.; Nadeau, C.; Volante, R. P., A Practical Enantioselective Synthesis of
Odanacatib, a Potent Cathepsin K Inhibitor, via Triflate Displacement of
an α-Trifluoromethylbenzyl Triflate. J. Org. Chem. 2009, 74 (4), 1605-
1610.
52.
Kiviranta, R.; Morko, J.; Alatalo, S. L.; NicAmhlaoibh, R.;
Risteli, J.; Laitala-Leinonen, T.; Vuorio, E., Impaired bone resorption in
cathepsin K-deficient mice is partially compensated for by enhanced
osteoclastogenesis and increased expression of other proteases via an
increased RANKL/OPG ratio. Bone 2005, 36 (1), 159-172.
34.
Liu, G.; Kong, L.; Shen, J.; Zhu, G., A regio- and stereoselective
entry to (Z)-β-halo alkenyl sulfides and their applications to access
stereodefined trisubstituted alkenes. Org. Biomol. Chem. 2014, 12 (14),
2310-2321.
53.
Pirapaharan, D. C.; Søe, K.; Panwar, P.; Madsen, J. S.;
Bergmann, M. L.; Overgaard, M.; Brömme, D.; Delaisse, J.-M., A Mild
Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive
Activity of Osteoclasts in Culture. Calcif. Tissue Int. 2019, 104 (1), 92-
101.
35.
Hoi-Yan, S.; Tak-Chung, C.; Chi-Ming, H.; Yungen, L.; Man-Kin,
W.; Chi-Ming, C., Electron-Deficient Alkynes as Cleavable Reagents for
the Modification of Cysteine-Containing Peptides in Aqueous Medium.
Chem. - Eur. J. 2009, 15 (15), 3839-3850.
54.
Thompson, S. K.; Halbert, S. M.; Bossard, M. J.; Tomaszek, T.
A.; Levy, M. A.; Zhao, B.; Smith, W. W.; Abdel-Meguid, S. S.; Janson, C. A.;
D’Alessio, K. J.; McQueney, M. S.; Amegadzie, B. Y.; Hanning, C. R.;
DesJarlais, R. L.; Briand, J.; Sarkar, S. K.; Huddleston, M. J.; Ijames, C. F.;
Carr, S. A.; Garnes, K. T.; Shu, A.; Heys, J. R.; Bradbeer, J.; Zembryki, D.;
Lee-Rykaczewski, L.; James, I. E.; Lark, M. W.; Drake, F. H.; Gowen, M.;
Gleason, J. G.; Veber, D. F., Design of potent and selective human
cathepsin K inhibitors that span the activeꢀsite. Proc. Natl. Acad. Sci.
1997, 94 (26), 14249.
36.
Barf, T.; Covey, T.; Izumi, R.; van de Kar, B.; Gulrajani, M.; van
Lith, B.; van Hoek, M.; de Zwart, E.; Mittag, D.; Demont, D.; Verkaik, S.;
Krantz, F.; Pearson, P. G.; Ulrich, R.; Kaptein, A., Acalabrutinib (ACP-
196):
A Covalent Bruton Tyrosine Kinase Inhibitor with a
Differentiated Selectivity and In Vivo Potency Profile. J. Pharmacol. Exp.
Ther. 2017, 363 (2), 240.
ACS Paragon Plus Environment